Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.
Scheuplein F, Renner F, Campbell JE, Campbell R, De Savi C, Eckmann J, Fischer H, Ge J, Green L, Jakob P, Kim JL, Kinkema C, McGinn K, Medina R, Müller A, Perez N, Perola E, Timsit Y, Traore T, Hopfer U, Tyanova S, Tzouros M, Wang R, Woessner R, Dorsch M, Bischoff JR.
Scheuplein F, et al. Among authors: jakob p.
Front Immunol. 2024 Oct 21;15:1411395. doi: 10.3389/fimmu.2024.1411395. eCollection 2024.
Front Immunol. 2024.
PMID: 39502695
Free PMC article.